On Mar. 24, 2020, Ology Bioservices and Inovio Pharma announced the Department of Defense (DOD) has awarded Ology Bioservices with a contract valued at $11.9 million to work with Inovio on DNA technology transfer to rapidly manufacture DNA vaccines.

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.